• US Preventive Services Task Force, Carol M Mangione, Michael J Barry, Wanda K Nicholson, Michael Cabana, David Chelmow, Tumaini Rucker Coker, Esa M Davis, Katrina E Donahue, John W Epling, Carlos Roberto Jaén, Alex H Krist, Martha Kubik, Li Li, Gbenga Ogedegbe, Lori Pbert, John M Ruiz, Melissa A Simon, James Stevermer, and John B Wong.
• University of California, Los Angeles.
• JAMA. 2022 May 24; 327 (20): 1992-1997.

ImportanceGlaucoma affects an estimated 2.7 million people in the US. It is the second-leading cause of irreversible blindness in the US and the leading cause of blindness in Black and Hispanic/Latino persons.ObjectiveTo update its 2013 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for glaucoma in adults.PopulationAdults 40 years or older who present in primary care and do not have signs or symptoms of open-angle glaucoma.Evidence AssessmentThe USPSTF concludes that the evidence is insufficient to assess the balance of benefits and harms of screening for glaucoma in adults. The benefits and harms of screening for glaucoma in adults are uncertain. More research is needed.RecommendationThe USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for primary open-angle glaucoma in adults. (I statement).

16 keywords...

hide…